Syteca Announces Participation in it-sa Expo&Congress 2024
8.10.2024 00:40:00 CEST | Business Wire | Press release
Syteca, formerly Ekran System, is pleased to announce its participation in the upcoming it-sa Expo&Congress 2024, taking place in Nuremberg, Germany from October 22-24, 2024. Syteca will unveil its enhanced cybersecurity platform, featuring new capabilities aimed at strengthening internal perimeter security.
Event Details:
- Location: NürnbergMesse GmbH, Messezentrum 1, 90471, Nuremberg, Germany
- Date: October 22-24, 2024
- Booth Number: 6-328
- Speaking Slot: Forum 6-B, October 22, 11:45 AM–12:00 PM (German session)
About it-sa Expo&Congress: it-sa Expo&Congress is Europe's premier trade fair for cybersecurity professionals, providing a platform for IT security experts and decision-makers from various industries to explore the latest innovations in security technologies. Since 2009, the event has been a hub for sharing knowledge and discovering cutting-edge solutions for critical infrastructure defense, cloud and mobile security, data protection, and industrial security.
Syteca at it-sa Expo&Congress 2024: At this year’s event, Syteca will showcase its advanced cybersecurity solutions, including:
- Privileged Access Management (PAM): Helping organizations implement the principle of least privilege by managing access to critical systems.
- User Activity Monitoring (UAM): Offering real-time visibility into user actions, ensuring immediate responses to suspicious activity.
- Workforce Password Management (WPM): Optimizing employee password security with time-based access restrictions and one-time passwords.
As part of our participation, Syteca will host a speaker session titled “Addressing NIS2 and DORA Requirements with PAM” on October 22, 2024, at Forum 6-B. Join us to learn how PAM solutions can help meet critical compliance requirements.
Meet the Syteca Team: Key members of Syteca’s leadership team will be present at the booth to discuss our platform and answer questions:
- Oleg Shomonko, Chief Executive Officer
- Ani Khachatryan, Chief Technology Officer
- Yevhen Zhurer, Head of Business Development
- Elena Gamasenko, Chief Marketing Officer
We also invite attendees to visit our booth for a coffee break, exclusive gifts, and an evening reception featuring craft beer and snacks. Schedule a meeting ahead!
About Syteca: Syteca, formerly known as Ekran System, delivers a comprehensive cybersecurity platform focused on internal perimeter protection. Trusted by organizations like Visa, Samsung, Panasonic, and UPS, Syteca has been recognized in Gartner’s 2023 Market Guide for Insider Risk Management Solutions and NIST Special Publication 1800-18. The platform’s modular structure provides robust solutions in privileged access management, user activity monitoring, and password management.
View source version on businesswire.com: https://www.businesswire.com/news/home/20241007065642/en/
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Andersen Consulting tilføjer House of Code for at styrke teknologi- og dataløsninger26.6.2026 20:01:00 CEST | Pressemeddelelse
Andersen Consulting forstærker sine kompetencer inden for teknologisk transformation gennem en samarbejdsaftale med House of Code, en global virksomhed med hovedkvarter i USA, der specialiserer sig i datadrevne platforme, automatisering og agentbaserede ai-løsninger. House of Code blev stiftet i 2001 og udvikler softwareløsninger samt yder rådgivning til energihandels- og finanssektoren med kunder, der spænder over hedgefonde, kapitalfonde og forsyningsvirksomheder. Virksomheden besidder dyb ekspertise inden for energihandel og risikostyring og hjælper organisationer med systemimplementering, forretningstransformation, dataautomatisering og ai-underbygget modernisering af arbejdsgange. Deres proprietære platform, Enterprise Platform for Integrated Compliance (EPIC), skaber en mere effektiv datastyring, automatiserer rapporteringsprocesser, forbedrer den driftsmæssige gennemsigtighed på tværs af virksomhedssystemer og skaber et fundament for opbygning af intelligente, agentbaserede arbe
Capco Recognized by OpenAI for Innovation and Responsible AI Leadership26.6.2026 20:00:00 CEST | Press release
Receives AI Governance & Risk Excellence Award at OpenAI Partner SummitCapco’s UK AI Lab wins OpenAI Codex Hackathon Global management and technology consultancy Capco, a Wipro company,has been recognized by OpenAI for both AI innovation and responsible AI leadership. Capco received the AI Governance & Risk Excellence Award at the recent OpenAI Partner Summit 2026 in San Francisco, highlighting Capco’s ability to deliver enterprise-grade AI outcomes in highly regulated environments. The award recognizes Capco’s expert advantage when helping financial services and energy organizations to scale AI with confidence, balancing innovation with strong governance to reduce risk, strengthen compliance and improve customer outcomes. This award follows Capco winning the OpenAI Codex Hackathon, where its UK AI Lab competed against more than 30 teams and over 100 participants from across the OpenAI partner ecosystem. Capco's winning entry Sentra – a consulting-led, AI-powered retail banking solutio
Incyte Announces Positive CHMP Opinion for Opzelura® (ruxolitinib) Cream for the Treatment of Adults with Moderate Atopic Dermatitis26.6.2026 13:30:00 CEST | Press release
If approved, Opzelura® (ruxolitinib) cream will be the first steroid-free, topical JAK treatment option in the European Union (EU) for adults with moderate atopic dermatitis (AD) for whom standard topical therapies have failedAD, the most common type of eczema which affects 230 million people globally,1 is a chronic, recurring, inflammatory and highly pruritic (itchy) skin condition that can have a significant impact on daily life2Phase 3 TRuE‑AD4 data supporting the positive CHMP opinion demonstrated that ruxolitinib cream met both co‑primary endpoints at Week 8, maintained disease control with as-needed treatment through Week 24 and was well tolerated3,4,5 Incyte (Nasdaq: INCY) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has issued a positive opinion recommending the approval of Opzelura® (ruxolitinib) cream for the treatment of moderate atopic dermatitis (AD) in adult patients for whom topical corticosteroids
Datroway® Recommended for Approval in the EU by CHMP as First-Line Treatment for Patients with Metastatic Triple Negative Breast Cancer Who Are Not Candidates for Immunotherapy26.6.2026 13:00:00 CEST | Press release
Recommendation based on TROPION-Breast02 phase 3 trial where Daiichi Sankyo and AstraZeneca’s Datroway showed a statistically significant and clinically meaningful improvement for the dual primary endpoints of overall survival and progression-free survival If approved, Datroway has potential to be the first TROP2 directed antibody drug conjugate for patients in EU with a demonstrated overall survival benefit as first-line treatment Datroway® (datopotamab deruxtecan) has been recommended for approval in the European Union (EU) as monotherapy for the first-line treatment of adult patients with unresectable or metastatic triple negative breast cancer (TNBC) who are not candidates for PD-1/PD-L1 inhibitor therapy. Datroway is a specifically engineered TROP2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use
DAYBU®(trofinetide) Recommended for Approval in the European Union by CHMP26.6.2026 12:49:00 CEST | Press release
-- European Commission decision expected in the coming months-- If approved, DAYBU®would become the first treatment for neurobehavioral symptoms of Rett syndrome in the European Union Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion following a re-examination procedure, recommending the granting of a marketing authorization for DAYBU® (trofinetide) for the treatment of neurobehavioral symptoms of Rett syndrome in adults and pediatric patients aged five years and older. If granted marketing authorization by the European Commission, DAYBU® would be the first therapy approved for this indication in the European Union (EU). “The CHMP’s positive opinion for DAYBU® is an important milestone in our mission to bring this innovative therapy to the EU, where there are no therapies specifically approved for the neurobehavioral symptoms of this devastating
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom